Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05909761 · ClinicalTrials.gov registry record
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
A clinical trial of Pregnancy Related and Neuromyelitis Optica Spectrum Disorder, sponsored by Amgen.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT05909761: Recruiting study of Pregnancy Related and Neuromyelitis Optica Spectrum Disorder, sponsored by Amgen.
NCT05909761 is a study of Pregnancy Related and Neuromyelitis Optica Spectrum Disorder that is actively recruiting participants, run by Amgen. The registered enrollment target is 60 participants, below the 1,962-participant average among 99 other Pregnancy Related trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05909761, a study of Pregnancy Related and Neuromyelitis Optica Spectrum Disorder, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational study to monitor female participants exposed to UPLIZNA during pregnancy. This study requires voluntary reporting of pregnancies in female participants with NMOSD exposed to UPLIZNA during pregnancy or within 6 months preceding conception. Pregnancy-related data, potential confounding factors and information related to pregnancy outcome will be collected. The schedule of office visits and all treatment regimens will be determined by the treating healthcare provider. Duration of the study is 10 years, at minimum.
Conditions Studied
Interventions
- DRUG UPLIZNA
Study Locations (1)
Colorado
- University of Colorado Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-04-15 |
| Est. Completion | 2032-10-31 |
What NCT05909761 shows while recruiting
NCT05909761 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,962-participant average among 99 other Pregnancy Related trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Pregnancy Related appearing as the primary indexed condition, and to 1 intervention - of which UPLIZNA is the first listed.
NCT05909761 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT05909761 about?
NCT05909761 is a clinical study titled "Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy". This is an observational study to monitor female participants exposed to UPLIZNA during pregnancy. This study requires voluntary reporting of pregnancies in female participants with NMOSD exposed to UPLIZNA during pregnancy or within 6 months preceding conception. Pregnancy-related data, potential c...
What is the current status of trial NCT05909761?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2026-04-15. Estimated completion is 2032-10-31.
What conditions does trial NCT05909761 study?
This clinical trial studies the following conditions: Pregnancy Related, Neuromyelitis Optica Spectrum Disorder.
What interventions are being tested in trial NCT05909761?
The interventions under investigation include: UPLIZNA (DRUG).
Who is sponsoring clinical trial NCT05909761?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05909761 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy Related
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05909761's enrollment target sits among peer trials
60 65th of 99 higher than 31 of 99 other Pregnancy Related trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pregnancy Related trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Antenatal Support for Iron Deficiency Anemia
RECRUITING · Phase 4
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
Mobile Application-based Exercise Intervention for Pregnant Women
RECRUITING · NA
-
Rigorous Evaluation of Yes and Know, a Fully Virtual Sexual Health and Well-Being Intervention for Youth
RECRUITING · NA
-
Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
RECRUITING
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI